Literature DB >> 1611186

Multiple sclerosis in Hokkaido, the northernmost island of Japan: prospective analyses of clinical features.

T Fukazawa1, K Tashiro, T Hamada, F Moriwaka, A Matsumoto, K Shima, Y Maruo.   

Abstract

We analyzed the clinical features of multiple sclerosis (MS) prospectively seen between July 1986 and October 1989 on Hokkaido island, the northernmost part of Japan. Clinical features were generally considered to be intermediate between the previous Japanese reports and those of Western countries. Devic's disease was rare and simultaneous bilateral visual loss at on set was not too common this series, differing from that previously reported of Japanese MS. The high incidence of acute transverse myelopathy and lesser involvement of the cerebellum, however, support the previous view. Further clinical and epidemiological studies will be necessary on this island.

Entities:  

Mesh:

Year:  1992        PMID: 1611186     DOI: 10.2169/internalmedicine.31.349

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG.

Authors:  I Nakashima; K Fujihara; I Miyazawa; T Misu; K Narikawa; M Nakamura; S Watanabe; T Takahashi; S Nishiyama; Y Shiga; S Sato; B G Weinshenker; Y Itoyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02-27       Impact factor: 10.154

2.  Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features.

Authors:  Ichiro Nakashima; Toshiyuki Fukazawa; Kohei Ota; Chiyoko Nohara; Yoko Warabi; Takashi Ohashi; Isabelle Miyazawa; Kazuo Fujihara; Yasuto Itoyama
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

3.  CSF pleocytosis and expansion of spinal lesions in Japanese multiple sclerosis with special reference to the new diagnostic criteria.

Authors:  Toshiyuki Fukazawa; Seiji Kikuchi; Ryuji Miyagishi; Yusei Miyazaki; Hikoaki Fukaura; Ichiro Yabe; Takeshi Hamada; Kunio Tashiro; Hidenao Sasaki
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.